NextCure Raises $67M in Series A Financing

nextcureNextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products, raised $67m in Series A financing.

Backers included Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer, Sofinnova Ventures, and Alexandria Venture Investments. In conjunction with the funding, David Kabakoff, Ph.D., executive partner of Sofinnova Ventures, will join Chairman of the company.

Founded in 2015 by Michael Richman, who will serve as its President and Chief Executive Officer, and Lieping Chen, M.D., Ph.D., United Technologies Endowed Professor of Cancer Research, Professor of Immunobiology, Dermatology, and Medicine at the Yale School of Medicine, NextCure is a biopharmaceutical company that leverages its proprietary platforms and know-how to identify novel and biologically relevant targets and develop immuno-oncology-based drugs.

Mr. Richman was previously President and Chief Executive Officer of Amplimmune, Inc., a biologics company focused on cancer and autoimmune diseases that was acquired by AstraZeneca plc.
Three other former members of the Amplimmune management team will join the NextCure management team:
– Solomon Langermann, Ph.D., who will serve as senior vice president of research;
– James Bingham, Ph.D., senior vice president of development and manufacturing and
– Linda Liu, Ph.D., vice president of translational research.



Join the discussion